Showing 1,277 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

Editor's pick
Yale News
8 January 2018
New & experimental HIV treatments

FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection

Editor's pick
Merck press release
8 January 2018
New & experimental HIV treatments

HIV Drugs in the Pipeline: Expected Approvals for 2018

Editor's pick
Infectious Disease Special Edition
31 December 2017
New & experimental HIV treatments

Dolutegravir and lamivudine potent and safe in people starting HIV therapy for the first time

News
28 December 2017
Treatment simplification strategies

Could we safely reduce the frequency of treatments for HIV-positive people?

Editor's pick
The Conversation
8 December 2017
New & experimental HIV treatments

FDA Approves Juluca, the First Two-Drug HIV Regimen

Editor's pick
Poz
22 November 2017
HIV treatment

Top 10 HIV Clinical Developments of 2017

Editor's pick
The Body Pro
19 November 2017
The search for a cure

European Cure Review concentrates on HIV therapeutic vaccines

News
16 November 2017
Pharmaceutical industry

GSK and Gilead go head to head as HIV drugs enter new phase

Editor's pick
Reuters
2 November 2017
Confidentiality, consent & medical ethics

DC biohackers and blockchainers take on HIV

Editor's pick
Technical.ly DC
1 November 2017
New & experimental HIV treatments

Symtuza as effective as multi-pill combination in previously untreated people with HIV

News
28 October 2017
People with limited treatment options

Fostemsavir controls viral load in half of people with highly drug-resistant HIV

News
28 October 2017
The search for a cure

ABX464 reduces HIV reservoir but doesn’t delay viral rebound

News
26 October 2017
HIV treatment

Symtuza protease inhibitor regimen maintains viral suppression for a year

News
13 October 2017
Antibody-based treatment

Long-acting monoclonal antibody effective against multidrug-resistant HIV

News
12 October 2017
Resistance

Antibody-Based HIV Tx Proves Durable

Editor's pick
MedPage Today
10 October 2017
New & experimental HIV treatments

Bictegravir-Containing Regimen Found to Be Non-Inferior to Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adult Patients with HIV

Editor's pick
Gilead press release
4 October 2017
Access to healthcare

The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir

Editor's pick
Medicines Patent Pool
4 October 2017
New & experimental HIV treatments

Promising HIV Treatments in Late-Stage Clinical Development

Editor's pick
P&T Community
2 October 2017
Access to healthcare

Single-pill HIV treatment to save SA R11bn – health ministry

Editor's pick
News24
25 September 2017
Access to healthcare

New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price

Editor's pick
UNAIDS
22 September 2017
New & experimental HIV treatments

Immune 'Cocktails' Likely Needed in HIV

Editor's pick
MedPage Today HIV/AIDS
21 September 2017
New & experimental HIV treatments

Maraviroc matches boosted protease inhibitor treatment over 96 weeks

News
11 September 2017
Undetectable viral load & treatment as prevention

IAS 2017: HIV Community Forum Video

August 2017